Astellas Pharma (TSE:4503) EPS (Basic) : 円30.60 (TTM As of Sep. 2024)

View and export this data going back to 1949. Start your Free Trial

What is Astellas Pharma EPS (Basic)?

Astellas Pharma's basic earnings per share (Basic EPS) for the three months ended in Sep. 2024 was 円20.06. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Sep. 2024 was 円30.60.

Astellas Pharma's EPS (Diluted) for the three months ended in Sep. 2024 was 円19.97. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was 円30.42.

Astellas Pharma's EPS without NRI for the three months ended in Sep. 2024 was 円19.93. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2024 was 29.85.

During the past 12 months, Astellas Pharma's average EPS without NRIGrowth Rate was 101.50% per year. During the past 3 years, the average EPS without NRI Growth Rate was -55.40% per year. During the past 5 years, the average EPS without NRI Growth Rate was -38.60% per year. During the past 10 years, the average EPS without NRI Growth Rate was -10.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Astellas Pharma's highest 3-Year average EPS without NRI Growth Rate was 89.70% per year. The lowest was -55.40% per year. And the median was 6.95% per year.

Astellas Pharma EPS (Basic) Historical Data

The historical data trend for Astellas Pharma's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Astellas Pharma EPS (Basic) Chart

Astellas Pharma Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

EPS (Basic)

Get a 7-Day Free Trial

104.15

64.93

67.08

54.24

9.51

Astellas Pharma Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EPS (Basic)	Get a 7-Day Free Trial															-0.81	8.09	-18.55	21.00	20.06

Astellas Pharma EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Astellas Pharma's Basic EPS for the fiscal year that ended in Mar. 2024 is calculated as

Basic EPS (A: Mar. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(17045	-	0)	/	1793.276
	=	9.50

Astellas Pharma's Basic EPS for the quarter that ended in Sep. 2024 is calculated as

Basic EPS (Q: Sep. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(35908	-	0)	/	1790.250
	=	20.06

EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was 円30.60

Astellas Pharma (TSE:4503) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Astellas Pharma EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Astellas Pharma's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Astellas Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Astellas Pharma Inc (TSE:4503) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

ALPMY:USA ALPMF:USA YPH:Germany YPH:Germany

Address

2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, JPN, 103-8411

Website

http://www.astellas.com

Astellas Pharma Inc is a specialty global pharmaceutical company. The company focuses on accelerating the discovery, development and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. The company operates its business in approximately 70 countries around the world. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.

Astellas Pharma Headlines

No Headlines